References
Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205: 751–758.
Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Nat Acad Sci USA 2009; 106: 9414–9418.
Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009; 144: 930–932.
Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008; 14: 3716–3721.
Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K et al. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. Int J Hematol 2010; 92: 320–325.
Cornejo MG, Kharas MG, Werneck MB, Le Bras S, Moore SA, Ball B et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 2009; 113: 2746–2754.
Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006; 10: 65–75.
Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 2011; 13: 504–513.
Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G et al. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 2011; 208: 901–908.
Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011; 43: 932–939.
Hornakova T, Chiaretti S, Lemaire MM, Foà R, Ben Abdelali R, Asnafi V et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 2010; 115: 3287–3295.
Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 2008; 112: 4220–4226.
Sato T, Toki T, Kanezaki R, Xu G, Terui K, Kanegane H et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br J Haematol 2008; 141: 681–688.
Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thomas G et al. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol 2011; 18: 314–323.
Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, Harris TM et al. The specificity of JAK3 kinase inhibitors. Blood 2008; 111: 2155–2157.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Michael Heinrich has equity interest in and is a consultant for Molecular MD. The other authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Bains, T., Heinrich, M., Loriaux, M. et al. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 26, 2144–2146 (2012). https://doi.org/10.1038/leu.2012.74
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.74
- Springer Nature Limited